-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, H5e3VeDdkI1/yKaRh+PDzPuFSm+X8IA5Kt0J5R9gMNMJ6dTlANAr6omi+840KRIA D1lssI3zkxKR7cnzudl9mw== 0001209191-05-065753.txt : 20051228 0001209191-05-065753.hdr.sgml : 20051228 20051228173429 ACCESSION NUMBER: 0001209191-05-065753 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20051223 FILED AS OF DATE: 20051228 DATE AS OF CHANGE: 20051228 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: OSCIENT PHARMACEUTICALS CORP CENTRAL INDEX KEY: 0000356830 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 042297484 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1000 WINTER STREET STREET 2: SUITE 2200 CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: 7813982300 MAIL ADDRESS: STREET 1: 1000 WINTER STREET STREET 2: SUITE 2200 CITY: WALTHAM STATE: MA ZIP: 02451 FORMER COMPANY: FORMER CONFORMED NAME: GENOME THERAPEUTICS CORP DATE OF NAME CHANGE: 19941215 FORMER COMPANY: FORMER CONFORMED NAME: COLLABORATIVE RESEARCH INC DATE OF NAME CHANGE: 19920703 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: EVNIN LUKE CENTRAL INDEX KEY: 0001134657 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-10824 FILM NUMBER: 051289589 BUSINESS ADDRESS: STREET 1: ONE CAMBRIDGE CENTER CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 6174259200 MAIL ADDRESS: STREET 1: THE JOHN HANCOCK TOWER STREET 2: 200 CLARENDON STREET, 54TH STREET CITY: BOSTON STATE: MA ZIP: 02116 4 1 bsf15835_bsf1le.xml MAIN DOCUMENT DESCRIPTION X0202 4 2005-12-23 0000356830 OSCIENT PHARMACEUTICALS CORP OSCI 0001134657 EVNIN LUKE C/O MPM ASSET MANAGEMENT 200 CLARENDON, 54TH FLOOR BOSTON MA 02116 1 0 0 0 Common Stock 2005-12-23 4 S 0 455000 2.3715 D 2576935 I See footnote Common Stock 2005-12-27 4 S 0 130000 2.3160 D 2446935 I See footnote Common Stock 2005-12-28 4 S 0 79200 2.3269 D 2367735 I See footnote The shares were sold as follows: 398,513 by BB BioVentures L.P. ("BB BV"), 51,255 by MPM BioVentures Parallel Fund, L.P. ("BV PF") and 5,232 by MPM Asset Management Investors 1998 LLC ("AM 1998"). MPM BioVentures I, L.P. ("BV I") and MPM BioVentures I LLC ("BV I LLC") are the direct and indirect general partners of BV PF. BAB BioVentures L.P. ("BAB BV") and BAB BioVentures, N.V. ("BAB NV") are the direct and indirect general partners of BB BV. The Reporting Person is a member of one of the shareholders of BAB NV and a manager of AM 1998 and BV I LLC. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by BB BV, BV PF, and AM 1998. The shares are held as follows: 2,256,984 by BB BV, 290,317 by BV PF and 29,634 by AM 1998. The Reporting Person disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein. The shares were sold as follows: 113,861 by BB BV, 14,644 by BV PF and 1,495 by AM 1998. The Reporting Person disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by BB BV, BV PF, and AM 1998. The shares are held as follows: 2,143,123 by BB BV, 275,673 by BV PF and 28,139 by AM 1998. The Reporting Person disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein. The shares were sold as follows: 69,367 by BB BV, 8,922 by BV PF and 911 by AM 1998. The Reporting Person disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by BB BV, BV PF, and AM 1998. The shares are held as follows: 2,073,756 by BB BV, 266,751 by BV PF and 27,228 by AM 1998. The Reporting Person disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein. /s/ Luke Evnin 2005-12-28 -----END PRIVACY-ENHANCED MESSAGE-----